

- of renal arteries, 1628, 1628t  
in respiratory disease evaluation, 1666, 1667f  
of thoracic aneurysm, 1639f  
time-of-flight, 440e-3f, 440e-7
- Magnetic resonance cholangiography, 283
- Magnetic resonance cholangiopancreatography (MRCP)  
of bile duct, 1892, 1895f, 2085t  
in chronic pancreatitis, 2099, 2100f  
in liver disease, 1993  
in pancreatic cancer, 555  
in pancreatic disease evaluation, 2087t, 2089  
in primary sclerosing cholangitis, 139e-3, 2061–2062
- Magnetic resonance elastography, 1993, 1999
- Magnetic resonance imaging (MRI)  
in adrenocortical carcinoma, 2323f  
in ankylosing spondylitis, 2171, 2172f  
for breast cancer screening, 480, 481t  
in CAH, 2328f  
in cardiac disease. *See* Cardiac magnetic resonance imaging (CMR)  
contraindications to, 440e-8t  
in Crohn's disease, 1954, 1955f  
in Cushing's syndrome, 2317, 2317f  
FLAIR. *See* Fluid-attenuated inversion recovery (FLAIR) MRI  
in hearing loss evaluation, 223  
in liver disease, 1993  
in Ménière's disease, 219  
in musculoskeletal disease evaluation, 2224t, 2225, 2225f  
in NETs, 572  
in neurologic disease. *See also* Neuroimaging, MRI  
acute disseminated encephalomyelitis, 441e-25f  
acute transverse myelitis, 441e-25f  
adrenoleukodystrophy, 441e-41f  
amyotrophic lateral sclerosis, 2632f  
Bell's palsy, 441e-23f, 2648f  
brachial plexopathy, 441e-30–31f  
brain abscess, 901, 902f  
brain metastases, 604f  
brain tumors, 441e-39f, 598, 600f, 601f  
CADASIL, 441e-18f  
candidal brain infection, 441e-8f  
cavernomas, 441e-38f  
cavernous malformation, 440e-7f  
central pontine myelinolysis, 1782, 1782f  
cerebral abscess, 440e-5f  
CNS aspergillosis, 441e-9–10f  
CNS tuberculosis, 441e-2f  
cocciidiomycosis meningitis, 441e-7f  
cranial epidural abscess, 905  
dementia, 174, 174f  
epidural metastases, 606f, 2653f  
FTD, 2603f  
Guillain-Barré syndrome, 441e-42f  
Hashimoto's encephalopathy, 441e-29f  
hemiplegic migraine, 441e-43f  
hepatic encephalopathy, 441e-42f  
histiocytosis, 441e-16f  
histoplasmosis of the pons, 441e-6f  
Huntington's disease, 441e-23f, 2622f  
hypoxic-ischemic encephalopathy, 1781f  
intracerebral hemorrhage, 2584  
intramedullary astrocytoma, 2654f  
Krabbe's disease, 441e-41f  
Leigh's disease, 441e-40f  
leptomeningeal metastases, 606f  
limbic encephalitis, 441e-1f  
MELAS, 441e-40f  
meningioma, 603f  
meningitis, 888  
mesial temporal lobe epilepsy, 2546f  
moyamoya disease, 441e-41f  
MS, 441e-27–28f, 441e-35f, 2664–2665, 2666f  
multiple system atrophy, 441e-22, 2641, 2641f  
neurocutaneous melanosis, 441e-37f  
neurofibromatosis type 2, 441e-36f  
neurosyphilis, 441e-3–5f  
primary central nervous system lymphoma, 601, 602f  
progressive multifocal leukoencephalopathy, 899  
retropharyngeal soft tissue mass, 441e-32f  
seizures, 2550  
sinonasal aspergillosis, 441e-10–11f  
spinal arteriovenous malformation, 2658f  
spinal cord infarction, 441e-25f  
spinal epidural abscess, 2655  
stroke, 2580, 2582f  
Sturge-Weber syndrome, 441e-38f  
subdural hematoma, 441e-34f  
superior sagittal sinus thrombosis, 441e-20–22f  
syringomyelia, 2658f  
thoracic meningioma, 2654f  
tuberous sclerosis, 441e-36f  
vertebral fractures, 441e-31–34f  
von Hippel-Lindau disease/syndrome, 441e-37f  
in osteomyelitis, 840  
of pituitary tumors, 2262, 2262f, 2278  
in polydipsia, 2278  
in respiratory disease evaluation, 1666, 1667f  
in rheumatoid arthritis, 2144, 2144f  
in sarcoidosis, 2209  
of sellar masses, 2262  
in spinal cord compression, 1791  
in spinal disorders, 114f, 116f  
in vestibular schwannoma, 603  
in viral encephalitis, 440e-6f, 895, 895f, 895t  
in Wernicke's disease, 1783f
- Magnetic resonance neurography, 440e-8
- Magnetoencephalography (MEG), 442e-3, 2550
- Mahaim fibers, 1481
- Ma huang (*Ephedra sinica*), 14e-3–4, 2547t
- Mahvash disease, 562, 569
- Maintenance dose, 36
- Majocchi's granuloma, 356
- Major depression, 2715, 2715t, 2716f. *See also* Depression/depressive disorders
- Major histocompatibility complex (MHC). *See* Human leukocyte antigen (HLA) complex
- MAL (methyl aminolevulinate), 386
- Malabsorption, surgery-related, 1927
- Malabsorption syndromes, **1932**  
approach to the patient, **1937**  
ataxia due to, 2630  
bacterial overgrowth syndromes. *See* Bacterial overgrowth syndromes  
celiac disease. *See* Celiac disease (gluten-induced enteropathy)  
classification of, 1946t  
clinical features of, 1937–1938, 1946t  
diagnosis of  
imaging, 1938, 1939f  
Schilling test, 350e-1t, 350e-1t, 1938  
small-intestinal mucosal biopsy, 1938–1940, 1940t, 1941f  
urinary D-xylose test, 1938  
pathophysiology of, 1946t  
protein-losing enteropathy, **1945**  
short bowel syndrome. *See* Short bowel syndrome  
tropical sprue. *See* Tropical sprue  
Whipple's disease. *See* Whipple's disease
- Maladie de Roger, 51e-5
- Malaria, **1368**  
in children, 1374  
chronic, 1374–1375  
climate change and, 151e-4, 151e-8, 151e-8f  
clinical features of, 152e-2t, 1372–1374, 1372t  
acidosis, 318, 1373  
encephalopathy, 780t, 783–784, 1373, 1373f, 1374t  
fever, 1372  
hematologic abnormalities, 1374  
hypoglycemia, 1373, 1381  
jaundice, 285  
liver dysfunction, 1374  
pulmonary edema, 1374, 1381  
renal failure, 1374, 1381, 1836t, 1849  
retinal hemorrhage, 1373, 1373f  
complications of, 1374, 1374t, 1381  
diagnosis of, 152e-2t, 245e-4t  
alternative procedures, 1377t  
blood films of parasites, 245e-2, 245e-6t, 250e-2–4f, 1375–1377, 1375–1377f, 1377t  
vs. *Brucella* infection, 194e-2  
laboratory findings, 1378  
serologic and molecular tests, 245e-6t, 1377–1378, 1377t  
drug research for, 13e-4  
epidemiology of, 151e-8, 151e-8f, 152e-2t, 245e-4t, 1370–1371, 1370f  
erythrocyte changes in, 1371  
etiology of. *See Plasmodium* spp.  
global considerations in, 14, 151e-4, 1370–1371, 1370f  
in HIV infection, 798, 1268, 1374  
host defense mechanisms in, 1371–1672  
incubation period for, 152e-2t  
pathogenesis of, 1368–1370, 1369f  
in pregnancy, 1374  
prevention of, 152e-2t  
chemoprophylaxis, 796, 796t, 1382–1384, 1383t. *See also specific drugs*  
in children, 1383t  
indoor residual spraying, 14  
insecticide-treated bed nets, 14  
organizational efforts, 14–15, 1382  
personal protection, 1382  
in pregnancy, 1382  
in travelers, 796, 796t, 1382–1384, 1383t  
prognosis of, 1373t  
resistance to  
G6PD deficiency and, 656, 1371  
hemoglobinopathies and, 633  
ovalocytosis and, 1371  
sickle cell anemia and, 442, 1371  
thalassemias and, 1371  
in returned traveler, 801–802, 802t  
transfusion-transmitted, 138e-3t, 138e-6, 1374  
transmission of, 1368–1370, 1369f  
treatment of  
antimalarial drugs, 246e-1–2t, 1380t. *See also specific drugs*  
drug resistance and, 14–15, 1379, 1381f  
Medicines for Malaria venture, 13e-4  
regimens for, 14–15, 1378–1379, 1378t, 1379, 1381  
in severe disease, 1378t, 1379  
in uncomplicated disease, 1378t, 1379, 1381  
in war veterans, 152e-1, 152e-2t, 152e-7
- Malassezia* spp., 1357
- Malassezia* spp. infections  
clinical features of, 1357  
diagnosis of, 1357  
epidemiology of, 1357  
folliculitis, 356, 1357  
tinea versicolor. *See* Tinea versicolor  
in transplant recipient, 921  
treatment of, 1357
- Malathion, 2746
- Mal del pinto. *See* Pinta
- Maldonado virus, 1309t
- Male feminization, paraneoplastic, 609t
- Male pseudohermaphroditism. *See* 46,XY disorders of sex development
- Male reproductive system disorders, **2360**  
in adulthood, **2363**  
aging-related. *See* Androgen deficiency androgen insensitivity syndromes. *See* Androgen insensitivity syndrome (AIS)  
diagnosis of, 2360–2361  
erectile dysfunction. *See* Erectile dysfunction (ED)  
gynecomastia. *See* Gynecomastia  
hypogonadism. *See* Hypogonadism  
hypogonadotropic hypogonadism. *See* Hypogonadotropic hypogonadism  
infertility, 2360, 2388, 2388f, 2389  
obesity and, 415e-6